References

1. Covens A, Carey M, Bryson P, et al: Systematic review of firstline chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 85:71-80, 2002.

2. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carbopla-tin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:31943200, 2003.

3. Gershenson DM, Kavanagh JJ, Copeland LJ, et al: Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 73:798-802, 1989.

4. Seltzer V, Vogl S, Kaplan B: Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 21:167-176, 1985.

5. Fisher RI, DeVita VT, Hubbard SP, et al: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761-763, 1979.

6. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18:106-115, 2000.

7. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991.

8. Hoskins PJ, O'Reilly SE, Swenerton KD: The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer 1:205-208, 1991.

9. Gore ME, Fryatt I, Wiltshaw E, et al: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207211, 1990.

10. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106, 2003.

11. Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carbo-platin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707, 2006.

12. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:33123322, 2001.

13. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994.

14. Cantu MG, Buda A, Parma G, et al: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20:1232-1237, 2002.

15. Markman M, Kennedy A, Webster K, et al: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141, 1999.

16. Navo M, Kunthur A, Badell ML, et al: Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 103:608-613, 2006.

17. Zweizig S, Roman LD, Muderspach LI: Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 53:121-122, 1994.

18. Robinson JB, Singh D, Bodurka-Bevers DC, et al: Hypersensitiv-ity reactions and the utility of oral and intravenous desensitiza-tion in patients with gynecologic malignancies. Gynecol Oncol 82:550-558, 2001.

19. Rose PG, Fusco N, Smrekar M, et al: Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 89:429-433, 2003.

20. Markman M, Hsieh F, Zanotti K, et al: Initial experience with a novel desensitization strategy for carboplatin-associated hyper-sensitivity reactions. J Cancer Res Clin Oncol 130:25-28, 2004.

21. Markman M: The dilemma of carboplatin-associated hypersen-sitivity reactions in ovarian cancer management. Gynecol Oncol 107:163-165, 2007.

22. Vergote I, Finkler N, del Campo J, et al: Single agent, canfos-famide versus pegylated doxorubicin or topotecan in 3rd line treatment of platinum refractory or resistant ovarian cancer: phase 3 study results. J Clin Oncol 25 (18S) (part 11): 966s-(Abstract #LBA55289), 2007.

23. Avall-Lundqvist E, Wimberger P, Gladieff L, et al: Pegylated liposomal doxorubicin-carboplatin vs. paclitaxel-carboplatin in relapsing sensitive ovarian cancer: a 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study. J Clin Oncol 26(15S):308s, 2008.

24. The International Collaborative Ovarian Neoplasm (ICON) Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505-515, 2002.

25. Markman M, Bookman MA: Second-line treatment of ovarian cancer. Oncologist 5:26-35, 2000.

26. Gordon AN, Tonda M, Sun S, et al: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1-8, 2004.

27. Pignata S, Ferrandina G, Scarfone G, et al: Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology 71:320-326, 2006.

28. Bristow RE, Lagasse LD, Karlan BY: Secondary surgical cytore-duction for advanced epithelial ovarian cancer. Cancer 78:20492062, 1996.

29. Markman M: Why study third-, fourth-, fifth-line chemotherapy of ovarian cancer? Gynecol Oncol 83:449-450, 2001.

30. Markman M: Viewing ovarian cancer as a "chronic disease": what exactly does this mean? Gynecol Oncol 100:229-230, 2006.

31. Holloway RW, Mehta RS, Finkler NJ, et al: Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87:8-16, 2002.

32. Sharma S, Neale MH, Di NF, et al: Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3:19-28,

2003.

33. Gallion H, Christopherson WA, Coleman RL, et al: Progressionfree interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer16:194-201, 2006.

34. Samson DJ, Seidenfeld J, Ziegler K, et al: Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22:3618-3630, 2004.

35. Schrag D, Garewal HS, Burstein HJ, et al: American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22:3631-3638,

2004.

36. Burger RA, Sill M, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007.

37. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007.

38. Fong PC, Boss DS, Carden CP, et al: AZD2281, a PARP inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J Clin Oncol 26(15S):295s, 2008.

39. Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancer deficient in DNA double-strand break repair. J Clin Oncol 26:37853790, 2008.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment